Literature DB >> 20679605

BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.

Jurgen Veeck, Santiago Ropero, Fernando Setien, Eva Gonzalez-Suarez, Ana Osorio, Javier Benitez, James G Herman, Manel Esteller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20679605     DOI： 10.1200/JCO.2010.30.1010

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  62 in total

1.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Authors:  Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2012 Jan-Feb

2.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 3.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

4.  The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women.

Authors:  Jyothi S Prabhu; Kanu Wahi; Aruna Korlimarla; Marjorrie Correa; Suraj Manjunath; N Raman; B S Srinath; T S Sridhar
Journal:  Tumour Biol       Date:  2012-02-24

5.  Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?

Authors:  Christopher Fosker; Julian W Adlard; Abeer Shaaban
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

6.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Authors:  Jung-Min Lee; John L Hays; Christina M Annunziata; Anne M Noonan; Lori Minasian; Jo Anne Zujewski; Minshu Yu; Nicolas Gordon; Jiuping Ji; Tristan M Sissung; William D Figg; Nilofer Azad; Bradford J Wood; James Doroshow; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2014-05-19       Impact factor: 13.506

7.  Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.

Authors:  Fengfeng Cai; Isabell Ge; Minghong Wang; Ewelina Biskup; Xiaoyan Lin; Xiaoyan Zhong
Journal:  Tumour Biol       Date:  2013-12-15

8.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

9.  Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.

Authors:  Rosa Murria; Sarai Palanca; Inmaculada de Juan; Cristina Alenda; Cecilia Egoavil; Francisco J Seguí; Zaida García-Casado; María J Juan; Ana B Sánchez; Ángel Segura; Ana Santaballa; Isabel Chirivella; Marta Llop; Gema Pérez; Eva Barragán; Dolores Salas; Pascual Bolufer
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

10.  A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Authors:  Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-08       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.